Senior insider sale
CHIEF FINANCIAL OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$1.52M
30.09K shares
What this filing means
HOHL BENJAMIN plans to sell 30.09K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $1.52M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 9/17/2026ACC: 0001974158-26-000103
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
30.09K
Shares to sell
$1.52M
Approx. market value
12.04K
Acquired (3 months)
1
Planned
3 completed
Securities Acquired — Last 3 Months2
Long shares from previous exercised options
N/A
12/13/2024
2.04KStock Option Exercise
N/A
2/13/2024
10KTotal acquired12.04K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
12/13/2024 | Long shares from previous exercised options N/A | 2.04K | — |
2/13/2024 | Stock Option Exercise N/A | 10K | — |
| Total | 12.04K | ||
Planned & Completed Dispositions4
Completed
—Completed
Units to sell
6.02K
Market value
$352.6K
8/17/2026
—Completed
Units to sell
6.02K
Market value
$316.8K
7/17/2026
—Completed
Units to sell
6.02K
Market value
$263.6K
6/17/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
12.04K
Market value
$591.2K
9/17/2026
Total
Units
30.09K
Value
$1.52M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
8/17/2026 | 6.02K | $352.6K | — | Completed |
7/17/2026 | 6.02K | $316.8K | — | Completed |
6/17/2026 | 6.02K | $263.6K | — | Completed |
| Planned — Approximate Date | ||||
9/17/2026 | 12.04K | $591.2K | NASDAQ | Planned |
| Total | 30.09K | $1.52M | ||